Nath Bio-Genes board meet on Jan 31, 2026 for Q3 FY26 results

Key development: board meeting on January 31

Nath Bio-Genes (India) Ltd has informed BSE that its Board of Directors will meet on January 31, 2026. The agenda includes considering and approving the company’s financial results as on December 31, 2025. The update is part of the company’s routine results calendar, with multiple quarterly-result board meetings disclosed over the last year.

For investors, the date matters because it sets the timeline for the next official financial update covering the period up to the end of December 2025. The company is listed as NSE: NATHBIOGEN and BSE: 537291.

Stock snapshot provided in the disclosure

The data shared alongside the board-meeting context shows the stock at ₹129.02, down 0.97%, with the timestamp Sat, 04 Apr 2026, 03:26 pm. This price point is not linked to the January 2026 board meeting announcement date, but it provides a reference level included in the same information set.

Board meeting history: quarterly cadence

The latest disclosed board meeting took place on January 31, 2026 for Quarterly Results. The company’s board-meeting list also shows earlier meetings for quarterly and audited results during 2025, indicating a regular schedule for results review and approvals.

Board meetings listed

What was disclosed earlier for June 2025 and September 2025 periods

The material also references earlier BSE intimations and outcomes:

• For 30 June 2025, the board meeting was scheduled on 11/07/2025, and the board approved standalone and consolidated unaudited financial results for that period.
• For 30 September 2025, the board meeting was scheduled on 13/11/2025 to consider and approve financial results as on that date, described as unaudited in the cited text.

These references establish that Nath Bio-Genes has been filing advance meeting intimations and publishing outcomes after board approvals, consistent with disclosure norms.

Dividend and corporate action references

The corporate actions table included in the source material mentions a final dividend of ₹2 per share, with an ex-date of 14 Aug 2025. It also lists an entry dated 29 Apr 2025 showing ₹2.00 dividend/share with the same ex-date.

While the January 31, 2026 board meeting agenda highlighted in the disclosure is about considering financial results, investors often track these meeting cycles since audited-results meetings have historically coincided with dividend decisions.

Operational and financial context from the company’s commentary

An earnings-call excerpt (dated Oct. 24, 2024, as provided) includes management commentary on credit rating and financial performance. The company stated that its credit rating saw a double upgradation from BBB- to BBB+. It also reported that H1 FY25 top line was ₹276.07 crore, up 7% year-on-year versus H1 FY24.

The same excerpt mentions a gross profit margin of 51%, H1 EBITDA of ₹42.18 crore, and profit after tax of ₹36.78 crore. It also stated that the company had zero debt, and that working capital improved.

H1 FY26 update and segment signals referenced in the material

A separate performance summary (release date Nov. 14, 2025, as cited) reports:

• H1 FY26 revenue: ₹319.90 crore, up 15.9% year-on-year
• Gross profit: up 21.3% year-on-year, attributed to product mix and improved margins
• PAT: ₹42.40 crore, up 15.3% year-on-year
• Working capital: increased from ₹283.75 crore (H1 FY25) to ₹413.47 crore (H1 FY26), attributed to higher receivables and inventory levels

It also highlights operational metrics such as cotton volume growth to 1.11 million packets (up 6%) and notes value growth across cotton, vegetables, paddy, maize, and plant nutrition solutions (PNS). The same material notes EBITDA margin compression linked to enhanced marketing schemes, despite maintaining gross margins.

Event timeline: results and communication touchpoints

The provided schedule also points to a structured communication rhythm around results. It states that the company’s earnings conference call was scheduled for Friday, 14 November 2025 at 12:30 PM IST. This date sits immediately after the 13 Nov 2025 board meeting listed for quarterly results, aligning with common practice where board-approved numbers are followed by an investor call.

Market impact: what investors can measure now

The primary confirmed market-moving item is the date of the upcoming board meeting on 31 Jan 2026 for results as on 31 Dec 2025. Until the company publishes the approved financials, investors are limited to previously disclosed performance indicators, including H1 FY26 revenue of ₹319.90 crore and PAT of ₹42.40 crore as cited in the material.

The working capital increase to ₹413.47 crore in H1 FY26, as referenced, is another measurable datapoint investors track, especially for agri-input and seeds businesses where inventory cycles and receivables can swing across seasons.

Why this board meeting matters in the seeds and agri-input cycle

For a company exposed to crop seasons and farmer demand, quarterly disclosures help investors track how volumes, pricing, and product mix are moving across cotton, paddy, maize, vegetables, and plant nutrition solutions. The same referenced summary flags external variables such as erratic monsoons and climate unpredictability, which can affect crop yields and farmer sentiment.

The January 31, 2026 meeting is therefore the next scheduled milestone when investors can reconcile operational trends with reported financial outcomes for the period ending December 2025.

Summary table of key disclosed datapoints

Conclusion

Nath Bio-Genes (India) has scheduled a board meeting on January 31, 2026 to consider financial results as on December 31, 2025, as disclosed to BSE. The next confirmed step for investors is the publication of board-approved results following that meeting, consistent with the company’s earlier quarterly disclosure pattern.